High proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesions

K Tateishi, M Tada, M Yamagata, H Isayama, Y Komatsu, T Kawabe, Y Shiratori, M Omata

Abstract

Background/Aims—It was recently reported that the quantitative analysis of mutant K-ras gene in pancreatic juice could be useful for the diagnosis of pancreatic cancer. This methodology was applied to patients with pancreatic cystic lesions.

Methods—DNA was extracted from pancreatic juice collected at the time of endoscopy with injection of secretin. The ratio of the K-ras mutant allele to the wild-type allele was measured by two methods to detect and semiquantify mutant K-ras gene: polymerase chain reaction/preferential homoduplex formation assay and enriched polymerase chain reaction/enzyme linked mini-sequence assay.

Results—A high frequency of K-ras mutation was detected (more than 2% of all K-ras genes) in six of 14 patients (43%) with pancreatic cysts. This frequency was similar to those detected in patients with pancreatic adenocarcinoma and in intraductal papillary neoplasms of the pancreas. In contrast, the frequency of mutation was low (less than 2%) in patients without either pancreatic cysts or pancreatic neoplasms.

Conclusions—K-ras gene mutation may be derived from duct cells in the pancreas with a high potential for tumorigenesis. Therefore careful follow up of patients with a pancreatic cyst is recommended if they are found to have a high level of the mutant gene in the pancreatic juice. (Gut 1999;45:737–740)

Keywords: pancreas; cyst; K-ras; pancreatic adenocarcinoma; quantitative analysis

Unlike qualitative detection of ras gene mutation, quantification of the mutant in pancreatic juice proved to be helpful for differential diagnosis of pancreatic tumours, as there was a higher amount of K-ras mutant associated with pancreatic carcinoma than in non-neoplastic cases. In a previous study, however, we found two cases that were exceptions: a high level of the mutant gene (more than 1%) was found in the pancreatic juice from two patients without pancreatic carcinoma or chronic pancreatitis. When we carefully re-examined the clinical features of these two cases, we noticed that the patients had cystic lesions in the pancreas that had no apparent relation to pancreatic neoplasms or chronic pancreatitis.

The most common cystic lesions of the pancreas are pseudocysts, accounting for more than half of pancreatic cystic lesions. The other cysts are neoplastic ones such as mucinous and serous cystadenocarcinoma, solitary or multiple retention cysts, and congenital cysts. Pancreatic cysts have been reported to co-exist in the pancreas of patients with carcinoma in situ, although the nature of the cysts is not clear.

Therefore, in this study, we semiquantitatively analysed the mutant ras gene in pancreatic juice from patients with cystic lesions in the pancreas without pancreatic neoplasms. Two useful assay kits, enriched polymerase chain reaction (PCR)/enzyme linked mini-sequence assay (ELMA) and PCR/preferential homoduplex formation assay (PHFA), were used.

Patients and methods

Patiens

A total of 76 patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) at Tokyo University Hospital were selected for quantitative analysis of ras gene mutation in the pancreatic juice. Of these, 14 patients with cystic lesions in the pancreas were analysed (table 1). These patients consisted of eight men and six women; their age ranged from 52 to 80 (mean 65). Pseudocysts or pancreatic cysts associated with pancreatic carcinoma were excluded. These patients had no history of pancreatitis, and the character of the pancreatic cyst was as follows: no obvious pancreatic neoplasms in the pancreas, no papillary structure.

Abbreviations used in this paper: ERCP, endoscopic retrograde cholangiopancreatography; PHFA, preferential homoduplex formation assay; ELMA, enzyme linked mini-sequence assay; IPN, intraductal papillary neoplasms of the pancreas.
in the cyst, no tendency to grow, no dilatation of the main pancreatic duct, and normal papilla of Vater. The maximum size of the cysts ranged from 3 to 40 mm in diameter, with an average of 19 mm. The number of cysts ranged from one to more than 10 and the average was two.

Twenty patients with pancreatic adenocarcinoma, 15 with intraductal neoplasms of the pancreas, six with chronic pancreatitis, and 21 without either pancreatic neoplasms or pancreatitis were used as controls for comparison (table 2).

METHODS

Pure pancreatic juice was collected from the pancreatic duct during ERCP with the injection of secretin. DNA was extracted from the pancreatic juice by the standard phenol/chloroform method. We recently obtained similar results to the semiquantitative assay of mutant K-ras gene using our modified allele specific PCR and two other methods: (a) PCR/PHFA (Wakunaga Pharmaceutical Corporation, Hiroshima, Japan and SRL Corporation, Tokyo, Japan); (b) enriched PCR/ELMA (BML Corporation, Tokyo, Japan). The two assays are available as handy kits. Therefore, mutant ras gene was analysed by these two methods in this study.

Briefly, PCR/PHFA is based on strand competition during hybridisation between a double labelled amplicon, which was prepared from biotin and dinitrophenyl labelled primers, and an unlabelled amplicon. Under a precisely controlled temperature gradient, the preferential formation of a homoduplex over a heteroduplex occurred. After annealing, the identical sequence of the double labelled and unlabelled amplicons resulted in a low population of rehybridised double labelled double stranded DNA as the result of strand exchange between them. Even when the two differed by a single base substitution, the double labelled molecule was regenerated efficiently because of preferential homoduplex formation. The regenerated double labelled molecules were captured on a streptavidin coated microtitre plate and quantified enzymatically with a chromogenic substance. This technique has been applied to HLA typing, and was also introduced for the semiquantitative analysis of mutant K-ras gene.

Enriched PCR/ELMA was based on the enrichment procedure of mutant K-ras gene described previously, and this was followed by the incorporation of biotin labelled nucleotide specific for the mutant gene, which was then quantified enzymatically with a chromogenic substance. Firstly, K-ras gene was amplified by PCR using a primer containing an artificial base substitution in order to mediate a restriction enzyme site that was limited to the wild type K-ras gene. After amplification, the amplicon was digested with a specific restriction enzyme in order to cleave a fragment of wild type allele and to select a fragment of the mutant allele. Second round PCR was performed to amplify the mutant gene selectively. Then the amplification product was captured by the oligomer which was designed to hybridise adjacent to the mutation site and was immobilised in a microtitration well. In a one nucleotide primer elongation step catalysed by Taq polymerase, a single biotin labelled nucleotide corresponding to a specific mutation was incorporated; this disclosed the presence of the mutation. Finally, the biotin labelled extended oligomer was semiquantified enzymatically with a chromogenic substance.

The results of the semiquantitative analysis were scored as (3+), (2+), (1+), (+−), and (−) according to the percentage of mutant ras gene. All materials were measured by both assays. Because similar amounts of mutant gene were obtained to those previously reported, the amount obtained by enriched PCR/ELMA was used for the results. The scores (3+), (2+), (1+), (+−), and (−) represented approximately more than 20%, 2–20%, 0.2–2%, less than 0.2%, and 0% (not detected) of the mutant respectively.

RESULTS

Mutant ras gene was detected in 10 of 14 patients with pancreatic cysts (fig 1). It was detected in high amounts (2+) or more in six of the 14 cases (43%). In cases of pancreatic carcinoma and intraductal papillary neoplasms of the pancreas (IPN), it was detected in high amounts (2+) or more in 10 of 20 cases (50%) and in 9 of 15 cases (60%)}
neoplasms of the pancreas.

intraductal papillary pancreatic carcinoma; IPN, other cases. Cancer, was relatively low in the pancreatic neoplasms. It pancreatic cysts and the proportion of GAT or GTT and added together. The two methods were counted the codons detected by the patient classification. All analysed according to pancreatic carcinoma, was more than twice the number of patients with the mutation, because different kinds of mutants were detected in the same patient in some cases. The proportion of GAT or GTT was 78% (21 of all the 27 mutations detected by the two different assays) in this study (fig 3). It was 89% (41 of 46) in patients with pancreatic cancer and 84% (32 of 38) in those with IPN. It was relatively low (50%, six of 12) in the other cases. Therefore it was evident that the frequency of GAT or GTT in patients with pancreatic cysts was also high, similar to that in patients with pancreatic neoplasms.

Discussion

There are many kinds of cysts in the pancreas, more than two thirds being pseudocysts. Pseudocysts are formed when the duct system is ruptured, resulting in leakage of pancreatic juice. Most of them are usually preceded by a history of pancreatitis or trauma, and there has also been a rare case caused by a primary neoplasm of the pancreas. In this study, pseudocysts were excluded by clinical history and radiological findings, although our series may include cystic lesions associated with mild chronic pancreatitis, which was not diagnosed by imaging modalities. Other common pancreatic cystic lesions are neoplastic, retention, and congenital cysts. Cystic neoplasms are divided into serous and mucinous adenomas (or adenocarcinomas). Serous cystadenoma is characterised by numerous tiny cysts ranging from 0.1 to 5 mm with a central scar. In our study, patient 12 had these characteristics, but mutant ras was not detected. In fact, it was reported that ras gene mutation was absent when serous cystadenoma tissue was analysed. Mucinous cystadenoma is a cystic pancreatic tumour that occurs almost exclusively in women in the pancreatic body or tail. The tumours are solitary, ranging from 20 to 35 mm in diameter. In our study, two patients (nos 3 and 7) with (2+) and (1+) amounts of mutant ras gene may be considered to belong to this category. The other kinds of cyst are solitary or multiple retention and congenital cysts. Most congenital cysts are associated with von Hippel-Lindau disease or hereditary polycystic kidney disease. In our series, there were no patients with clinical features of these diseases. Retention cysts occur secondary to obstruction of the pancreatic duct system and most of them are small. Therefore most of the cystic lesions in patients other than nos 3, 7, and 12 in this study could be retention cysts.

A high rate of mutation of the K-ras gene in the pancreatic juice was detected unexpectedly in most patients with pancreatic cysts as well as in patients with pancreatic carcinoma and IPN.
The fact that the frequency of the mutational type of codon was also similar to that of pancreatic neoplasms may suggest that some neoplastic change had already occurred in pancreas with these cystic lesions, although such a lesion was not radiologically detected.

The patients in our study showed no clinical or radiological features of pancreatic carcinoma or chronic pancreatitis. However, retention cysts are usually formed in association with chronic pancreatitis or pancreatic cancer.\(^{11}\) Small and multiple cysts were found during 15% of 100 autopsies of patients with pancreatic cancer.\(^{12}\) Another study reported that pancreatic cysts co-existed in the pancreas of patients with carcinoma in situ, and that this was the earliest feature of pancreatic cancer.\(^{13}\)

These findings may indicate that small cystic lesions in the pancreas reflect the premalignant state of the pancreas.

An alternative possibility is that they represent early lesions of IPN. IPN is another type of pancreatic neoplasm. There is no definite name for this tumour, and IPN, intraductal papilloma, intraductal papillary mucinous tumour, mucin-producing cancer, mucin-hypersecreting neoplasm, and ductectatic cystadenoma or mucinous tumors represent a distinct group of pancreatic neoplasms. There is no definite name for this tumour, and IPN, intraductal papillary-mucinous tumors of the pancreas: clinico-pathological features, outcomes, and nomenclature. Gastroenterology 1996;110:1909–18.

Of course, it is too early to draw any definite conclusions at this point. The number of patients is too small, and long term follow up of such patients will be required. However, little is known about the risk factors for pancreatic cancer, which makes it particularly difficult to find carcinoma of the pancreas at an early stage.\(^{20}\) New radiological techniques such as endoscopic ultrasonography, which is superior to ERCP for the detection of small lesions in the pancreas, have been introduced,\(^{21}\) and it has become easier to detect small cysts. Thus we should search carefully for small cystic lesions in the pancreas, and quantify \(K-ras\) mutation in the pancreatic juice if the presence of a pancreatic cyst is discovered. If the mutant gene is detected in high amounts, the cyst should be followed up carefully because it may undergo malignant changes.
High proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesions

K Tateishi, M Tada, M Yamagata, H Isayama, Y Komatsu, T Kawabe, Y Shiratori and M Omata

Gut 1999 45: 737-740
doi: 10.1136/gut.45.5.737

Updated information and services can be found at:
http://gut.bmj.com/content/45/5/737

These include:

References
This article cites 25 articles, 4 of which you can access for free at:
http://gut.bmj.com/content/45/5/737#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Pancreas and biliary tract (1949)
- Pancreatic cancer (660)
- Gastrointestinal hormones (848)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/